Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tremelimumab - AstraZeneca

X
Drug Profile

Tremelimumab - AstraZeneca

Alternative Names: Anti CTLA 4 monoclonal antibody - AstraZeneca; CP-675; CP-675,206; IMJUDO; Ticilimumab

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Cancer Research Institute; Dana-Farber Cancer Institute; Immunocore; MedImmune; Pfizer; University of Alabama at Birmingham
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Liver cancer; Non-small cell lung cancer
  • Phase III Bladder cancer; Head and neck cancer; Malignant-mesothelioma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase II Biliary cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Germ cell cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer
  • Phase I/II Haematological malignancies; Malignant melanoma
  • No development reported Diffuse large B cell lymphoma; Gynaecological cancer; Myelodysplastic syndromes; Vulvovaginal cancer

Most Recent Events

  • 01 May 2024 University of Alabama at Birmingham terminates a I/II trial for Cholangiocarcinoma (Combination therapy) in USA (IV) due to slow accrual and study sponsor decision (NCT04989218)
  • 31 Jan 2024 AstraZeneca initiates the phase IIIb TRITON trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in USA (IV) (NCT06008093)
  • 18 Jan 2024 Efficacy and adverse events data from a phase Ib DEPARTURE trial in Liver cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top